Buprenorphine Hcl And Naloxone Hcl Tablet
FDA Label NDC 50268-144

57 label sections · Submitted to the FDA by Avpak · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Avpak for the product Buprenorphine Hcl And Naloxone Hcl (NDC 50268-144). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding recent major changes, 1 indications and usage, 2.2 important dosage and administration information, 2.4 maintenance, 2.5 method of administration, 2.6 clinical supervision, 2.7 unstable patients, 2.8 discontinuing treatment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.